NASDAQ$TSHA
Taysha Gene Therapies Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Taysha Gene Therapies reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.
Taysha Gene Therapies reported a net loss of $50.4 million for the fourth quarter of 2021. The company is prioritizing key registration-directed programs in GAN and Rett syndrome and expects its cash runway to extend into Q4 2023.
- Reported positive clinical efficacy and safety data for high dose cohort and long-term durability data across all therapeutic dose cohorts for TSHA-120 in GAN.
- Clinical Trial Application (CTA) approved by Health Canada in March 2022.
- Reported positive preliminary clinical safety data for first-generation construct in CLN7 Batten disease from UTSW-sponsored clinical trial.
- Prioritizing key value-driving registration-directed programs, GAN and Rett syndrome.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$0
Forward guidance
Taysha Gene Therapies anticipates several milestones in 2022, including regulatory updates for TSHA-120 in GAN, first-in-human preliminary Phase 1/2 data for TSHA-102 in Rett syndrome, initiation of clinical development for TSHA-105 in SLC13A5 deficiency, continued clinical development for TSHA-118 in CLN1 disease, and continued clinical development of the first-generation construct for CLN7 disease.
Tailwinds
- Regulatory update for TSHA-120 in GAN by mid-2022
- First-in-human preliminary Phase 1/2 data for TSHA-102 in Rett syndrome by year-end 2022
- Initiation of clinical development for TSHA-105 in SLC13A5 deficiency in 2022
- Continued clinical development for TSHA-118 in CLN1 disease in 2022
- Continued clinical development of the first-generation construct for CLN7 disease in 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro